Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents
Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents
批准号:
7218329
负责人:
LYNN W MAINES
金额:
$95.31万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-06-01 至 2009-06-30
关键词:
AcuteAcute Toxicity TestsAddressAnimal ModelAnimalsAttenuatedBiological ModelsBlood VesselsBruch&aposs basal membrane structureCanis familiarisCell Differentiation processChoroidal NeovascularizationChronicClassClinical TreatmentClinical TrialsCyclic GMPDevelopmentDiabetic RetinopathyDiseaseDisease modelEndothelial CellsEvaluationEventExtravasationEye diseasesGoalsHumanInvestigational New Drug ApplicationLaboratory ProceduresLasersMediatingMediator of activation proteinMetabolismModelingMolecular TargetNude MiceOxygenPathologyPharmaceutical PreparationsPhasePhase I Clinical TrialsProceduresRattusResearchRetinalRetinal DiseasesRetinopathy of PrematurityRoleSafetySignal PathwaySphingolipidsTNF geneTherapeuticTherapeutic AgentsToxic effectToxicologyTreatment ProtocolsTumor Necrosis Factor-alphaTumor Necrosis FactorsVascular DiseasesVascular Endothelial Growth FactorsVascularizationangiogenesisbiological adaptation to stresshuman TNF proteinhuman diseasein vivo Modelinhibitor/antagonistinnovationkinase inhibitorneovascularizationnovelnovel therapeuticsprogramsprotective effectresponsesphingosine 1-phosphatesphingosine kinasesubcutaneous
中文摘要
描述(由申请人提供):该计划的目标是开发新型的人神经鞘氨酸激酶(SK)抑制剂,作为视网膜和脉络膜血管疾病的有效治疗剂。由于其在鞘磷脂代谢中的关键作用,我们将SK作为一种创新的分子靶点,用于开发治疗与过度血管生成相关的眼部疾病的新药。鞘磷脂被认为是应激反应、细胞分化和增殖的关键介质,并被认为是介导血管内皮生长因子(VEGF)和肿瘤坏死因子-a(TNFa)的作用,而这两种因子在眼病中起着关键作用。我们推测,由SK在视网膜内皮细胞内产生的鞘氨醇-1-磷酸(S1P)对血管内皮生长因子的反应是导致血管渗漏和新生血管形成的一连串事件的关键,而血管泄漏和新生血管是眼病的标志性病理。因此,SK是开发新的治疗药物的关键分子靶点。由于SK在调节细胞增殖中的关键作用,我们正在开发SK抑制剂作为治疗眼病的药物。在这个项目的第一阶段,我们证明了我们专有的SK抑制剂可以阻断由血管内皮生长因子和肿瘤坏死因子诱导的人视网膜内皮细胞的信号通路。重要的是,我们进一步证明,在两个动物模型中,给予我们的SK抑制剂可以减少血管泄漏,包括裸鼠的血管内皮生长因子诱导的皮下模型和STZ治疗的大鼠为期3个月的糖尿病视网膜病变模型。两种模型均未观察到对动物的毒性。这些研究首次证明了SK抑制剂在治疗眼病方面可能是有效的。在这个第二阶段的项目中,我们将评估SK抑制剂在另外两个眼部疾病体内模型中的治疗活性,包括氧诱导的视网膜病变和激光诱导的脉络膜新生血管。此外,我们还将确定眼病模型中动物的最佳治疗方案。最后,FDA要求的研究将完成,以便提交SK抑制剂ABC294640的调查性新药申请。将解决以下具体目标:1.目的:评价ABC294640对氧性视网膜病变的保护作用。2.)目的:评价ABC294640对激光诱导的脉络膜新生血管的保护作用。3.)用ABC294640完成cGMP的合成和IND直接毒理学研究。总体而言,建议的研究代表了一种有重点的方法来评估SK抑制剂ABC294640并将其用于治疗眼病的临床试验。这将提供对这一创新分子靶标的一流抑制剂的快速评估。
英文摘要
DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents for retinal and choroidal vascular diseases. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development of new drugs for the treatment of ocular diseases associated with excessive angiogenesis. Sphingolipids are being increasingly recognized as key mediators of stress responses, cell differentiation and proliferation, and are known to mediate the effects of vascular endothelial growth factor (VEGF) and tumor necrosis factor-a (TNFa) that are of central importance in eye disease. We hypothesized that sphingosine-1-phosphate (S1P) produced by SK within retinal endothelial cells in response to VEGF is critical to the cascade of events that results in the vascular leakiness and neovascularization that are hallmark pathologies in eye disease. Therefore, SK is a key molecular target for the development of new therapeutic agents. Because of the pivotal role of SK in regulating proliferation, we are developing SK inhibitors to be used as drugs to treat eye disease. In Phase I of this program, we demonstrated that our proprietary SK inhibitors block signaling pathways induced by VEGF and TNFa in human retinal endothelial cells. Importantly, we further demonstrated that administration of our SK inhibitors reduces vascular leakiness in two animal models, including a VEGF-induced subcutaneous model in nude mice and a 3-month diabetic retinopathy model in STZ-treated rats. No toxicity to the animals was observed in either model. These studies provide the first proof-of-principle demonstration that SK inhibitors are likely to be effective in the treatment of eye disease. In this Phase II project, we will evaluate the therapeutic activity of the SK inhibitor in two additional in vivo models of ocular disease, including oxygen-induced retinopathy and laser-induced chorodial neovascularization. Additionally, we will determine the optimal schedule for treatment of the animals in the eye disease models. Finally, FDA-required studies will be completed to enable the submission of an Investigational New Drug application for the SK inhibitor ABC294640. The following Specific Aims will be addressed: 1.) To evaluate the protective effects of ABC294640 in a model of oxygen-induced retinopathy. 2.) To evaluate the protective effects of ABC294640 in a model of laser-induced choroidal neovascularization. 3.) To complete cGMP synthesis and IND-directed toxicology studies with ABC294640. Overall, the studies proposed represent a focused approach to evaluate and move the SK inhibitor ABC294640 into clinical trials for the treatment of ocular disease. This will provide rapid evaluation of the first-in-class inhibitor of this innovative molecular target.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mitigation of Radiation-Induced Pulmonary Fibrosis by a Sphingosine Kinase Inhibi
-
批准号:8455896
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2013
-
负责人:LYNN W MAINES
-
依托单位:
Mitigation of Radiation-Induced Pulmonary Fibrosis by a Sphingosine Kinase Inhibi
-
批准号:8603222
-
项目类别:
-
资助金额:$29.34万
-
财政年份:2013
-
负责人:LYNN W MAINES
-
依托单位:
Phase 1 Study of ABC294640 for the Treatment of Pancreatic Cancer
-
批准号:8216986
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2012
-
负责人:LYNN W MAINES
-
依托单位:
Treatment of Inflammatory Bowel Disease with Ceramidase Inhibitors
-
批准号:8387733
-
项目类别:
-
资助金额:$31.69万
-
财政年份:2012
-
负责人:LYNN W MAINES
-
依托单位:
Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents
-
批准号:7455032
-
项目类别:
-
资助金额:$92.17万
-
财政年份:2005
-
负责人:LYNN W MAINES
-
依托单位:
Sphingosine Kinase Inhibitors as Anti-IBD Agents
-
批准号:7050857
-
项目类别:
-
资助金额:$17.66万
-
财政年份:2005
-
负责人:LYNN W MAINES
-
依托单位:
Sphingosine Kinase Inhibitors of Diabetic Retinopathy
-
批准号:6933599
-
项目类别:
-
资助金额:$12.93万
-
财政年份:2005
-
负责人:LYNN W MAINES
-
依托单位:
Sphingosine Kinase Inhibitors as Anti-IBD Agents
-
批准号:7154216
-
项目类别:
-
资助金额:$81.98万
-
财政年份:2005
-
负责人:LYNN W MAINES
-
依托单位:
Sphingosine Kinase Inhibitors as Anti-IBD Agents
-
批准号:7278825
-
项目类别:
-
资助金额:$87.46万
-
财政年份:2005
-
负责人:LYNN W MAINES
-
依托单位:
GLIOBLAST-13: A NOVEL ANTI-BRAIN TUMOR THERAPEUTIC
-
批准号:6210670
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2000
-
负责人:LYNN W MAINES
-
依托单位: